Tocilizumab in chronic active antibody-mediated rejection: a randomized controlled open-label multi-center trial (INTERCEPT study)

被引：0

作者：

Streichart, Lillian ^{[1
]}

Felldin, Marie ^{[1
]}

Ekberg, Jana ^{[1
]}

Mjornstedt, Lars ^{[1
]}

Lindner, Per ^{[1
]}

Lennerling, Annette ^{[1
]}

Brocker, Verena ^{[2
]}

Molne, Johan ^{[2
]}

Holgersson, Jan ^{[3
,4
]}

Daenen, Kristien ^{[5
]}

Wennberg, Lars ^{[6
]}

Lorant, Tomas ^{[7
]}

机构：

[1] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Transplant Inst,Inst Clin Sci, Gothenburg, Sweden

[2] Sahlgrens Univ Hosp, Dept Pathol, Gothenburg, Sweden

[3] Univ Gothenburg, Inst Biomed, Dept Lab Med, Gothenburg, Sweden

[4] Sahlgrens Univ Hosp, Dept Clin Immunol & Transfus Med, Gothenburg, Sweden

[5] Sahlgrens Univ Hosp, Dept Nephrol, Gothenburg, Sweden

[6] Karolinska Univ Hosp, Dept Transplantat Surg, Stockholm, Sweden

[7] Univ Uppsala Hosp, Sect Transplantat Surg, Dept Surg Sci, Uppsala, Sweden

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

1985

引用

页码：I2675 / I2676

页数：2

共 50 条

[1] Tocilizumab in chronic active antibody-mediated rejection: a randomized controlled open-label multi-center trial (INTERCEPT study)
Streichart, Lillian
Felldin, Marie
Ekberg, Jana
Mjoernstedt, Lars
Lindner, Per
Lennerling, Annette
Broecker, Verena
Moelne, Johan
Holgersson, Jan
Daenen, Kristien
Wennberg, Lars
Lorant, Tomas
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
[2] Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)
Streichart, Lillian
Felldin, Marie
Ekberg, Jana
Mjoernstedt, Lars
Lindner, Per
Lennerling, Annette
Brocker, Verena
Molne, Johan
Holgersson, Jan
Daenen, Kristien
Wennberg, Lars
Lorant, Tomas
Baid-Agrawal, Seema
TRIALS, 2024, 25 (01)
[3] Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)
Lillian Streichart
Marie Felldin
Jana Ekberg
Lars Mjörnstedt
Per Lindnér
Annette Lennerling
Verena Bröcker
Johan Mölne
Jan Holgersson
Kristien Daenen
Lars Wennberg
Tomas Lorant
Seema Baid-Agrawal
Trials, 25
[4] Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients
Boonpheng, Boonphiphop
De Castro, Iris Camille C.
Ng, Yue-Harn
Blosser, Christopher
Bakthavatsalam, Ramasamy
Gimferrer, Idoia
Smith, Kelly
Leca, Nicolae
CLINICAL TRANSPLANTATION, 2023, 37 (05)
[5] Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
Farsad Eskandary
Michael Dürr
Klemens Budde
Konstantin Doberer
Roman Reindl-Schwaighofer
Johannes Waiser
Markus Wahrmann
Heinz Regele
Andreas Spittler
Nils Lachmann
Christa Firbas
Jakob Mühlbacher
Gregor Bond
Philipp F. Halloran
Edward Chong
Bernd Jilma
Georg A. Böhmig
Trials, 20
[6] Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial
Falconer, Henrik
Palsdottir, Kolbrun
Stalberg, Karin
Dahm-Kahler, Pernilla
Ottander, Ulrika
Lundin, Evelyn Serreyn
Wijk, Lena
Kimmig, Rainer
Jensen, Pernille Tine
Eriksson, Ane Gerda Zahl
Maenpaa, Johanna
Persson, Jan
Salehi, Sahar
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (06) : 1072 - 1076
[7] Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
Eskandary, Farsad
Duerr, Michael
Budde, Klemens
Doberer, Konstantin
Reindl-Schwaighofer, Roman
Waiser, Johannes
Wahrmann, Markus
Regele, Heinz
Spittler, Andreas
Lachmann, Nils
Firbas, Christa
Muehlbacher, Jakob
Bond, Gregor
Halloran, Philipp F.
Chong, Edward
Jilma, Bernd
Boehmig, Georg A.
TRIALS, 2019, 20 (1)
[8] Study Protocol for Multi-Center, Open-Label , Randomized Controlled Trial for Assessing the Efficacy and Safety of Electroacupuncture for Cold Hypersensitivity in Hands and Feet
Lee, Kyou-Young
Lee, Dong-Nyung
Kwon, Na-Yoen
Kim, Dong-Il
Yu, Jun-Sang
Sun, Seung-Ho
JOURNAL OF PHARMACOPUNCTURE, 2025, 28 (01) : 47 - 56
[9] Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study
Rhee, Sang Youl
Chon, Suk
Ahn, Kyu Jeung
Woo, Jeong-Taek
Lee, Moon-Kyu
Park, Kyong Soo
Cha, Bong Soo
Baik, Sei-Hyun
Park, Joong Yeol
Lee, Kwan Woo
Lee, In-Kyu
Park, Tae Sun
Kim, In Joo
Lee, Jung Min
Lee, Jung Hwa
Lim, Jeong Hyun
Cho, Jae Won
Kweon, Meera
Lee, Ji-Hyun
Cho, Young Jung
Lee, Jee-Hyun
Lim, Sung-Chul
Choi, Jin Sun
Hong, Jeongim
Lim, Hyun Jung
Cho, Dong-Hyeok
Chun, Sung Wan
Kim, So Hun
Sohn, Seo Young
Lee, Hyeok
Hwang, You Cheol
Jeon, Justin Y.
Lee, Mi Kyoung
Kang, Eunjeong
Choi, Jihye
DIABETES & METABOLISM JOURNAL, 2019, 43 (01) : 49 - 58
[10] Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients
Sangermano, Maria
Negrisolo, Susanna
Antoniello, Benedetta
Vadori, Marta
Cozzi, Emanuele
Benetti, Elisa
HUMAN IMMUNOLOGY, 2024, 85 (05)

← 1 2 3 4 5 →